Shares of Moderna Inc fell nearly 10per cent after it lost a bid to invalidate a U.S. patent owned by Arbutus Biopharma that poses a potential obstacle to Moderna’s efforts to develop next-generation vaccines, including a coronavirus vaccine.
Moderna loses challenge to Arbutus patent on vaccine technology
